Berkeley, CA, March 23, 2021 – GeneTether Inc., a Bay Area biotech company focused on developing technologies to increase the correction efficiency of targeted genome editing technologies, today announced that it has closed the first and second tranches of its common stock private placement. The Company expects to complete a third and final tranche in the second quarter of 2021.
Mr. Har Grover, CEO of GeneTether, stated: “We are quite pleased with investors’ high level of interest in our TNT™ platform technology, as evidenced by this global syndicate, which includes investors in seven countries on five continents. The funding received through these two tranches and the anticipated third tranche will allow the GeneTether team to continue building out a robust data package evidencing the increases in gene editing efficiency that can be achieved through a combination of our DNA Template-Nuclease-Tethering platform and a CRISPR-mediated editing technology such as CRISPR-Cas9. We look forward to further updates as the results of our R&D program become available.”
This release does not constitute an offer to sell or the solicitation of an offer to buy any security.
GeneTether has developed a proprietary method to conjugate, or “tether,” donor DNA templates to targeted genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs. We refer to this as our DNA Template-Nuclease Tethering, or TNT™, Platform. In ex vivo experimentation combining our TNT™ Platform technology with CRISPR-Cas9, the TNT™ Platform has been shown to increase editing efficiency to >50%.
For more information, visit www.genetether.com.
For inquiries, please contact us at:
Har Grover, CEO